Nitric Oxide as a Therapeutic Agent against SARS-CoV-2: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Shuqi Xiao
,
Zhiming Yuan
,
Yi Huang

Nitric oxide (NO) is a key player in both the cardiopulmonary and immune systems, which has already been reported as a worthy candidate for use in the treatment of human coronavirus infections, including COVID-19, because of its antivirus activity and its beneficial effects in the treatment of clinical complications in patients. In fact, inhaled nitric oxide (iNO), as a potent vasodilator, was approved to improve oxygenation in term and near-term neonates, and has been used in clinical settings. Along with its putative antiviral affect, iNO can reduce inflammatory cell-mediated lung injury by inhibiting neutrophil activation, lowering pulmonary vascular resistance, and decreasing edema in the alveolar spaces, thus collectively enhancing ventilation/perfusion matching.

  • SARS-CoV-2 infection
  • COVID-19
  • NO
  • antiviral
  • anti-inflammation
  • NO therapy

1. Introduction

The novel coronavirus disease (also known as COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been swept across the world and emerged as a major health concern [1] in the recent three years. According to the World Health Organization (WHO), 769,806,130 confirmed cases of COVID-19 have been reported, including 6,955,497 deaths [2]. The fatality rate has varied significantly by region and age groups. Despite commencing vaccination with initially satisfactory efficacy, the SARS-CoV-2 infection has been going on because of many emergences of variants strains, though it has been declared to be a non-concerning disease now. For example, the Omicron variants have caused global concern owing to their great increased transmissibility and immune evasion capability despite its lesser pathogenicity. Therefore, confirmatory polymerase chain reaction tests to identify the SARS-CoV-2 infection and basic preventive measures, such as social distancing and wearing a mask, remain important precautions against COVID-19 [3]. The emergence of the Omicron variants has highlighted the need for more alternative therapies with various modes to reduce the impact of mutated strains such as inhibiting SARS-CoV-2 entry/fusion, RNA replication and protease inhibitors, vaccines and drug-free therapies like plasma therapy, etc., and proposed lifestyle factors (such as nitrate-rich and other natural product diets and exercise) as preventive strategies [4][5].

2. SARS-CoV-2 and COVID-19

SARS-CoV-2 is a member of the coronaviruses (CoV) family, which are enveloped and single-stranded positive-sense RNA viruses with (typically) a genome of ~30 kilobase (kb). Coronaviruses also have been named after the protruding coronary spikes on the virus’s surface [6]. Similar with other β-coronaviruses genome organization, SARS-CoV-2 consists of un-translated regions(UTRs) at both 5′ and 3′ end regions and fourteen functional open reading frames (ORFs) that encode for different structural proteins, non-structural proteins (nsps), and accessory proteins [7][8]. There are four structural proteins: the spike (S) protein encoded by the S gene is the site on the virus’s surface responsible for binding to the host receptor; the M protein encoded by the M gene shapes the virions and directs envelop formation and provides the matrix for nucleocapsid attaching and budding; the E protein encoded by the E gene is involved in the virus’s assembly and release, contributing to the pathogenesis; and the N gene encodes the N protein, which binds to the RNA genome to maintain the virus’s stability. The ORF1a and ORF1b encode sixteen highly conserved nuclear shuttle proteins (nsp1-nsp16) that are essential for viral replication and transcription processes. Nine accessory proteins provide a selective advantage in the infected host [9][10][11].
Apart from SARS-CoV-2, the other two coronaviruses were found to transmit to human populations, trigger acute respiratory syndromes in humans, and even cause severe outbreak clusters after overcoming the species barrier over the recent two decades, namely the severe acute respiratory syndrome (SARS-CoV-1) in 2002 and the Middle East respiratory syndrome (MERS-CoV) in 2012 [12][13]. SARS-CoV-2 shares 80% and 50% similarity with SARS-CoV-1 and MERS-CoV, respectively [14]. All of them belong to the β-coronavirus genera in the coronaviruses family which infects the respiratory tract, causing atypical pneumonia, and also affects the function of other organs like the liver, heart, kidney, gastrointestinal system, and central nervous system [15].
COVID-19 is either asymptomatic or mild, with the most common symptoms being fever, headache, dry cough, shortness of breath, and myalgia in about 80–90% of cases, and only around 10% of the infected patients have severe infection with dyspnea, hypoxemia, and extensive radiological involvement of the lung parenchyma. In some critical cases (less than 5%), this virus is likely to cause acute lung injury (ALI), acute respiratory distress syndrome (ARDS), sepsis, and subsequent multi-organ failure leading to respiratory failure and eventually death, which are very similar to the pathological features of SARS and MERS [16][17]. Thus, the symptoms vary from individual to individual, ranging from an asymptomatic infection to severe respiratory failure. Gastrointestinal disorders, such as diarrhea, nausea, and vomiting, are reported to a lesser extent. Some patients have also experienced loss of smell and nasal obstruction. This indicated a potential neurotropism of SASR-CoV-2 that may invade the central nervous system [18]. The individuals with pre-existing comorbidities like obesity, hypertension, diabetes, chronic obstructive pulmonary disease (COPD), cardiovascular disease, cerebrovascular disease, and autoimmune disease or immunosuppressed condition are at a much higher risk of severe COVID-19 disease [19].
Although SARS-CoV-2 mainly infects bronchial ciliated epithelium and pulmonary type II cells initially, electron imaging has detected leftover virus particles in endothelial cells. SARS-CoV-2’s entry into host cells is mediated by binding to the host cellular receptor, angiotensin-converting enzyme 2 (ACE2), which is located on the host cell surface of the target organs, with a higher affinity than with the one measured with SARS-CoV-1. ACE2s are highly expressed in type II alveoli epithelial cells, which serve as the primary targets for viral attacks [20]. Studies identified that the virus significantly impacts other organs with the development of myocarditis, gastrointestinal disturbances, renal ailments, and irregular blood pressure, and the presence of ACE2 on the epithelial and endothelial lining of the liver, heart, kidney, pancreas, gastrointestinal tract, genital organs, thyroid, blood vessels, and so on is considered partly responsible for this [21]. In the case of SARS-CoV-2, S protein, which is required for viral entry, has two regions, S1 and S2. S1 has a receptor-binding domain (RBD) that mediates direct contact with ACE2 to form the S protein RBD-ACE2 complex, whereas S2 is involved in subsequent membrane fusion [22].
After SARS-CoV-2 enters the target cells, the virus is disassembled to release viral RNA into the cytoplasm for translation of non-structural proteins and structural proteins and replication of genome. The translated replicase components rearrange the endoplasmic reticulum (ER) into double-membrane vesicles (DMVs) that facilitate viral replication of genomic and subgenomic RNAs. The latter are translated into accessory and viral structural proteins to facilitate virus particle formation. The virus particles germinated in the endoplasmic reticulum–Golgi intermediate compartment (ERGIC) were exocytosed into the extracellular compartment for the propagation of the infection in other target cells [23].
In parallel with the ongoing viral replication, the viral RNA genome release into the cytoplasm is detected by intracellular pattern recognition receptors (PRRs), innate immune sensors such as the endosomal Toll-like receptor, and cytosolic retinoic acid-inducible gene I-like receptors. Following PRR activation, molecular signaling cascades culminate in the activation of downstream transcription factors, such as nuclear factor-κB (NF-κB), to produce numerous pro-inflammatory cytokines (including interferon (IFN)-α, IFN-γ, interleukin (IL)-1β, IL-6, IL-12, IL-18, IL-33, tumor necrosis factor (TNF)-α, and transforming growth factor (TGF)-β) and chemokines (such as chemokine ligand (CCL) 2, CCL3, CCL5, CXC chemokine ligand (CXCL) 8, CXCL9, and CXCL10) in the form of a “cytokine storm” [23][24]. Multiple clinical symptoms are strongly connected with the release of these cytokines.
Another pathway pertaining to the pathogenesis of COVID-19 is the ACE2-angiotensin 1-7 (Ang 1-7) axis. It is known that ACE converts angiotensin I (Ang I) into the pro-inflammatory peptide angiotensin II (Ang II), and ACE2 metabolizes Ang II to produce Ang 1-7. The SARS-CoV-2 infection downregulates ACE2 expression by internalizing it with viral particles from the host cell surface and fails to catalyze the conversion of Ang II to Ang 1-7, resulting in Ang II accumulation. A high concentration of Ang II can cause increased inflammatory responses and reactive oxygen species (ROS) [25][26]. A large number of activated pro-inflammatory cytokines and chemokines were found in the serum of patients with severe COVID-19, including the membrane forms of epidermal growth factor (EGF) family members, IL-6 receptor, and TNF-α, and developed into a strong cytokine storm [27]. When high inflammation persists for a long time, it damages many tissues and organs and contributes to an imbalance of ROS, which leads to vasoconstriction.

3. Role of NO in SARS-CoV-2 Infection

3.1. Antiviral Effect

From the early days, it was warranted that NO has a rather broad spectrum of antiviral effects and inhibits viral replication, including ectromelia virus, vaccinia, vesicular stomatitis virus, adenovirus, murine CMV (MCMV), murine retrovirus, rhinovirus, herpes simplex-1 viruses, HIV, hantavirus, influenza, Japanese encephalitis virus, and (most importantly) coronavirus [28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49]. More notably, NO has been shown to impair SARS-CoV and SARS-CoV-2 replication in light of the COVID-19 pandemic because of their similar infection processes [50][51][52][53]. Two NO-mediated antiviral mechanisms were proposed, and were later experimentally verified, as follows:
(1)
 NO decreased the palmitoylation level of S protein, thereby interfering with binding to the target receptor on the host cell. Three different studies demonstrated the potential of NO compounds in the inhibition of SARS-CoV replication in a concentration-dependent manner [50][52][53], and the effect of NO on S protein was also investigated. The results showed that the NO donor-S-nitroso-N-acetylpenicillamine (SNAP) treatment significantly reduced the number of palmitoylated S protein, and the intercellular fusion was significantly decreased. Also, the entry efficiency of the pseudo-type virus was significantly lower after SNAP treatment, and the virus infection rate decreased by about 70% [50].
(2)
 NO affected replication-related cysteine proteases which directly inhibited viral RNA replication. Similar to the Coxsackievirus 3C cysteine protease, SARS-CoV-2 3CL cysteine protease may be a potential target for S-nitrosation, causing a suppression of the protease activity and a resultant decrease in viral replication [42]. The in vitro study by Akaberi et al. showed that SARS-CoV-2 3CL recombinant protease was covalently inhibited by SNAP through the transfer of nitrosonium ions (NO+s) to the protease cysteine residue, and the observed reduction in SARS-CoV-2 protease activity was consistent with S-nitrosylation of the enzyme active site cysteine. Although the viral replication was not completely abolished, SNAP delayed or completely prevented the development of the viral cytopathic effect in treated cells [51]. In addition, the analysis of proteolytic degradation of the viral polypeptide showed that the content of the nucleocapsid N protein was drastically decreased in the presence of SNAP and that high-molar-mass (non-processed) polypeptide content was increased [50][53].

3.2. Effect on Inflammation

Inflammation is a critical defensive mechanism for inactivating pathogens, removing irritants, and paving the way for tissue repairs. However, excessive inflammation causes injury. Studies have shown that NO, as a ubiquitous signaling molecule, plays a role in almost every stage of inflammation [54].
For example, NO suppresses the production of a large number of cytokines in lymphocytes, eosinophils, monocytes, and other immune cells, including key cytokines in the inflammatory response [40][55][56]. The different and inappropriate inflammatory response associated with the SARS-CoV-2 infection in the context of the COVID-19 illness was described above (SARS-CoV-2 and COVID-19 section). Moreover, multiple reports indicated that NF-κB is involved in the upregulation of inflammatory responses in patients with the SARS-CoV-2 infection as a potential main regulator of this process [57]. Regulation of NF-κB activation by NO has been well investigated for its involvement in various physiological and pathological conditions [58]. The most common form of active NF-κB is a heterodimer consisting of the protein subunits p50 and p65. After the IκB-kinase (IKK) complex phosphorylates the cytoplasmic inhibitor factor IκB, which normally sequesters NF-κB in an inactive form in the cytosol, NF-κB is translocated into the nucleus and induces a plethora of pro-inflammatory gene expressions. Here, NO represses IκB-kinase through S-nitrosylation and S-nitrosylation of IKKβ at Cys179, and p50 at Cys62 inhibits NF-κB-dependent DNA binding, promoter activity, and gene transcription, leading to the subsequent inflammatory response [59].

An additional factor that contributes to the excessive inflammatory responses is relevant to ACE2. ACE and ACE2 serve opposing physiological functions. After ACE cleaves Ang I to Ang II, Ang II binds its receptor to constrict blood vessels. In addition, ACE inhibits NO production, promoting ROS and inflammation. An excess of ROS damages endothelial dysfunction, permeable vessels, and lipid membrane peroxidation [60]. On the contrary, ACE2 inactivates Ang II and generates Ang 1-7, which promote endothelial production of NO, as both potent vasodilators and inhibitors of ACE. The accumulation of Ang II caused by the downregulation of ACE2 expression in the SARS-CoV-2 infection can induce vasoconstriction and act as a pro-inflammatory cytokine via AT1R. The AngII-AT1R axis induces inflammatory cytokines, including TNFα and IL-6-soluble (s)IL-6R, via activating disintegrin and metalloprotease 17 (ADAM17), followed by the activation of the IL-6 amplifier (IL-6 AMP), which describes enhanced NF-κB activation machinery via the coactivation of NF-κB and the signal transducer and activator of transcription-3 (STAT3) [27]. 

Inflammation-induced platelet activation, which can lead to increased coagulation and consequent diseases, can be lessened by NO [61]. NO maintains physiological vascular homeostasis in tissues and protects blood vessels from damage with platelets and circulating cells, and the decrease in endothelial NO production is a sign of endothelial dysfunction and thrombotic events [62]. The decreased or ceased release of NO following endothelial cell dysfunction leads to the accumulation of free Ca2+ in vascular smooth muscle cells, continuous vasoconstriction, and subsequently a blood hypercoagulable state. When blood vessels are damaged, platelets quickly gather to the injured site to form platelet clots and a complex with plasma factor VIIa, whose subsequent interaction with extravascular tissue factor initiates the action of thrombin (via conversion of inactive protease factor X into the active protease factor Xa). Thrombin then converts soluble fibrin into insoluble fibrin, which makes the platelet clot entangled with blood cells to form a thrombus. 

3.3. Effects on Vasodilation

NO can serve as an effective vasodilator regulator. It effectively relaxes smooth muscle cells and dilates blood vessels to improve oxygenation and reduce pulmonary vascular resistance and promoter oxygen inhalation, thus increasing the blood flow of capillaries, increasing the exchange gas with alveoli, and accelerating oxygen circulation in the body, which may improve respiratory symptoms.
In detail, NO reacts with oxygen to form nitrogen dioxide and nitrite, resulting in pulmonary vasodilatation. Further, nitrosylation of the cysteine residue of the haemoglobin β subunit leads to the formation of a stable derivative that retains vasodilatory properties which can increase blood flow and oxygen delivery to the system’s vasculature [63]. NO regulates the vascular tone via the cyclic guanosine monophosphate (cGMP)-dependent mechanism. It binds to soluble guanylate cyclase (sGC) and activates it, resulting in the production of intracellular cyclic guanosine monophosphate (cGMP). cGMP reduces the intracellular Ca2+ concentration and relaxes smooth muscle cells. The reduction in calcium reduces the ability of myosin light-chain kinase (MLCK) to phosphorylate the myosin molecule, preventing cross-bridging and thus enhancing the relaxation of smooth muscle cells and promoting blood flow. It also activates potassium channels, leading to hyperpolarization and relaxation [64].

4. Application of NO in Clinical Treatment of COVID-19

Based on the aforementioned antiviral, anti-inflammatory, and anti-thrombotic effects, NO, also as a potent and selective pulmonary vasodilator, has been appraised as an attractive agent that may be beneficial to COVID-19 patients’ therapy, with or without ARDS [65][66]. Further, NO inhalation therapy showed promising potency in the 2003 SARS outbreak [67]. Many case series, cohort studies, retrospective investigations, and clinical trials that investigated different strategies of NO administration under various conditions were conducted and analyzed to discuss the use of exogenous NO therapy among patients with COVID-19.

Many clinical observations and studies have demonstrated that iNO treatment produced an acute improvement in the systemic oxygenation process in hypoxemic patients and prevented the progression of hypoxemic respiratory failure [68][69]. High-dose NO (160–200 ppm for 30 min) was safely administered to pregnant females with severe COVID-19 pneumonia and was associated with improved oxygenation, respiratory rate, and cardiopulmonary system function and a decrease in systemic inflammation [70]. Another strategy for iNO administration in COVID-19 is the administration of a long-term, constant NO insufflation at low doses, which may increase antiviral activity (dose and time-dependent) and reduce the severity of the disease and time to recovery in patients with COVID-19 [71][72]. Intriguingly, a randomized clinical trial using iNO among healthcare workers was conducted to prevent them from being infected with the SARS-CoV-2 during their work. The use of iNO in conjunction with pharmaceutical vasodilators, such as almitrine and prostaglandin, has also shown a positive clinical value as a rescue therapy to enhance oxygen levels in patients with COVID-19 [73][74][75].

This entry is adapted from the peer-reviewed paper 10.3390/ijms242417162

References

  1. Abrams, E.M.; Szefler, S.J. COVID-19 and the impact of social determinants of health. Lancet Respir. Med. 2020, 8, 659–661.
  2. World Health Organization. COVID-19 Dashboard. 2023. Available online: https://covid19.who.int/ (accessed on 16 August 2023).
  3. Wang, Y.; Tian, H.; Zhang, L.; Zhang, M.; Guo, D.; Wu, W.; Zhang, X.; Kan, G.L.; Jia, L.; Huo, D.; et al. Reduction of secondary transmission of SARS-CoV-2 in households by face mask use, disinfection and social distancing: A cohort study in Beijing, China. BMJ Glob. Health 2020, 5, e002794.
  4. Kobayashi, J. Lifestyle-mediated nitric oxide boost to prevent SARS-CoV-2 infection: A perspective. Nitric Oxide 2021, 115, 55–61.
  5. Alkafaas, S.S.; Abdallah, A.M.; Hussien, A.M.; Bedair, H.; Abdo, M.; Ghosh, S.; Elkafas, S.S.; Apollon, W.; Saki, M.; Loutfy, S.A.; et al. A study on the effect of natural products against the transmission of B.1.1.529 Omicron. Virol. J. 2023, 20, 191.
  6. Fehr, A.R.; Perlman, S. Coronaviruses: An overview of their replication and pathogenesis. Methods Mol. Biol. 2015, 1282, 1–23.
  7. Lu, R.; Zhao, X.; Li, J.; Niu, P.; Yang, B.; Wu, H.; Wang, W.; Song, H.; Huang, B.; Zhu, N.; et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 2020, 395, 565–574.
  8. Wu, F.; Zhao, S.; Yu, B.; Chen, Y.-M.; Wang, W.; Song, Z.-G.; Hu, Y.; Tao, Z.-W.; Tian, J.-H.; Pei, Y.-Y.; et al. A new coronavirus associated with human respiratory disease in China. Nature 2020, 579, 265–269.
  9. Chen, Y.; Liu, Q.; Guo, D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J. Med. Virol. 2020, 92, 2249.
  10. Bartlam, M.; Xu, Y.; Rao, Z. Structural proteomics of the SARS coronavirus: A model response to emerging infectious diseases. J. Struct. Funct. Genom. 2007, 8, 85–97.
  11. Ziebuhr, J. Molecular biology of severe acute respiratory syndrome coronavirus. Curr. Opin. Microbiol. 2004, 7, 412–419.
  12. Cheng, V.C.; Lau, S.K.; Woo, P.C.; Yuen, K.Y. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin. Microbiol. Rev. 2007, 20, 660–694.
  13. Zumla, A.; Hui, D.S.; Perlman, S. Middle East respiratory syndrome. Lancet 2015, 386, 995–1007.
  14. Tang, X.; Wu, C.; Li, X.; Song, Y.; Yao, X.; Wu, X.; Duan, Y.; Zhang, H.; Wang, Y.; Qian, Z.; et al. On the origin and continuing evolution of SARS-CoV-2. Natl. Sci. Rev. 2020, 7, 1012–1023.
  15. Liu, C.; Zhou, Q.; Li, Y.; Garner, L.V.; Watkins, S.P.; Carter, L.J.; Smoot, J.; Gregg, A.C.; Daniels, A.D.; Jervey, S.; et al. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Cent. Sci. 2020, 6, 315–331.
  16. Xu, Z.; Shi, L.; Wang, Y.; Zhang, J.; Huang, L.; Zhang, C.; Liu, S.; Zhao, P.; Liu, H.; Zhu, L.; et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 2020, 8, 420–422.
  17. Takahashi, N.; Abe, R.; Hattori, N.; Matsumura, Y.; Oshima, T.; Taniguchi, T.; Igari, H.; Nakada, T.-A. Clinical course of a critically ill patient with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). J. Artif. Organs 2020, 23, 397–400.
  18. Pascarella, G.; Strumia, A.; Piliego, C.; Bruno, F.; Del Buono, R.; Costa, F.; Scarlata, S.; Agrò, F.E. COVID-19 diagnosis and management: A comprehensive review. J. Intern. Med. 2020, 288, 192–206.
  19. Callender, L.A.; Curran, M.; Bates, S.M.; Mairesse, M.; Weigandt, J.; Betts, C.J. The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19. Front. Immunol. 2020, 11, 1991.
  20. Zhao, Y.; Zhao, Z.; Wang, Y.; Zhou, Y.; Ma, Y.; Zuo, W. Single-Cell RNA Expression Profiling of ACE2, the Receptor of SARS-CoV-2. Am. J. Respir. Crit. Care Med. 2020, 202, 756–759, Erratum in Am. J. Respir. Crit. Care Med. 2021, 203, 782.
  21. Qi, F.; Qian, S.; Zhang, S.; Zhang, Z. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Biochem. Biophys. Res. Commun. 2020, 526, 135–140.
  22. Wang, Q.; Zhang, Y.; Wu, L.; Niu, S.; Song, C.; Zhang, Z.; Lu, G.; Qiao, C.; Hu, Y.; Yuen, K.Y.; et al. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell 2020, 181, 894–904.
  23. Harrison, A.G.; Lin, T.; Wang, P. Mechanisms of SARS-CoV-2 Transmission and Pathogenesis. Trends Immunol. 2020, 41, 1100–1115.
  24. Li, X.; Geng, M.; Peng, Y.; Meng, L.; Lu, S. Molecular immune pathogenesis and diagnosis of COVID-19. J. Pharm. Anal. 2020, 10, 102–108.
  25. England, J.T.; Abdulla, A.; Biggs, C.M.; Lee, A.Y.Y.; Hay, K.A.; Hoiland, R.L.; Wellington, C.L.; Sekhon, M.; Jamal, S.; Shojania, K.; et al. Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes. Blood Rev. 2021, 45, 100707.
  26. A Clark, I. The advent of the cytokine storm. Immunol. Cell Biol. 2007, 85, 271–273.
  27. Hirano, T.; Murakami, M. COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome. Immunity 2020, 52, 731–733.
  28. Croen, K.D. Evidence for antiviral effect of nitric oxide. Inhibition of herpes simplex virus type 1 replication. J. Clin. Investig. 1993, 91, 2446–2452.
  29. Karupiah, G.; Xie, Q.W.; Buller, R.M.; Nathan, C.; Duarte, C.; MacMicking, J.D. Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase. Science 1993, 261, 1445–1448.
  30. Akarid, K.; Sinet, M.; Desforges, B.; Gougerot-Pocidalo, M.A. Inhibitory effect of nitric oxide on the replication of a murine retrovirus in vitro and in vivo. J. Virol. 1995, 69, 7001–7005.
  31. Bi, Z.; Reiss, C.S. Inhibition of vesicular stomatitis virus infection by nitric oxide. J. Virol. 1995, 69, 2208–2213.
  32. Harris, N.; Buller, R.M.; Karupiah, G. Gamma interferon-induced, nitric oxide-mediated inhibition of vaccinia virus replication. J. Virol. 1995, 69, 910–915.
  33. Karupiah, G.; Harris, N. Inhibition of viral replication by nitric oxide and its reversal by ferrous sulfate and tricarboxylic acid cycle metabolites. J. Exp. Med. 1995, 181, 2171–2179.
  34. Mĕlková, Z.; Esteban, M. Inhibition of vaccinia virus DNA replication by inducible expression of nitric oxide synthase. J. Immunol. 1995, 155, 5711–5718.
  35. Hermann, E.; Idziorek, T.; Kusnierz, J.-P.; Mouton, Y.; Capron, A.; Bahr, G.M. Role of nitric oxide in the regulation of lymphocyte apoptosis and HIV-1 replication. Int. J. Immunopharmacol. 1997, 19, 387–397.
  36. Lin, Y.L.; Huang, Y.L.; Ma, S.H.; Yeh, C.T.; Chiou, S.Y.; Chen, L.K.; Liao, C.L. Inhibition of Japanese encephalitis virus infection by nitric oxide: Antiviral effect of nitric oxide on RNA virus replication. J. Virol. 1997, 71, 5227–5235.
  37. Zaragoza, C.; Ocampo, C.J.; Saura, M.; McMillan, A.; Lowenstein, C.J. Nitric oxide inhibition of coxsackievirus replication in vitro. J. Clin. Investig. 1997, 100, 1760–1767.
  38. Karupiah, G.; Chen, J.-H.; Nathan, C.F.; Mahalingam, S.; MacMicking, J.D. Identification of nitric oxide synthase 2 as an innate resistance locus against ectromelia virus infection. J. Virol. 1998, 72, 7703–7706.
  39. Persichini, T.; Colasanti, M.; Lauro, G.M.; Ascenzi, P. Cysteine nitrosylation inactivates the HIV-1 protease. Biochem. Biophys. Res. Commun. 1998, 250, 575–576.
  40. Sanders, S.P.; Siekierski, E.S.; Porter, J.D.; Richards, S.M.; Proud, D. Nitric oxide inhibits rhinovirus-induced cytokine production and viral replication in a human respiratory epithelial cell line. J. Virol. 1998, 72, 934–942.
  41. Rimmelzwaan, G.F.; Baars, M.M.; de Lijster, P.; Fouchier, R.A.; Osterhaus, A.D. Inhibition of influenza virus replication by nitric oxide. J. Virol. 1999, 73, 8880–8883.
  42. Saura, M.; Zaragoza, C.; McMillan, A.; Quick, R.A.; Hohenadl, C.; Lowenstein, J.M.; Lowenstein, C.J. An antiviral mechanism of nitric oxide: Inhibition of a viral protease. Immunity 1999, 10, 21–28.
  43. Flodström, M.; Horwitz, M.S.; Maday, A.; Balakrishna, D.; Rodriguez, E.; Sarvetnick, N. A critical role for inducible nitric oxide synthase in host survival following coxsackievirus B4 infection. Virology 2001, 281, 205–215.
  44. Noda, S.; Tanaka, K.; Sawamura, S.-A.; Sasaki, M.; Matsumoto, T.; Mikami, K.; Aiba, Y.; Hasegawa, H.; Kawabe, N.; Koga, Y. Role of nitric oxide synthase type 2 in acute infection with murine cytomegalovirus. J. Immunol. 2001, 166, 3533–3541.
  45. Sanders, S.P.; Kim, J.; Connolly, K.R.; Porter, J.D.; Siekierski, E.S.; Proud, D. Nitric oxide inhibits rhinovirus-induced granulocyte macrophage colony-stimulating factor production in bronchial epithelial cells. Am. J. Respir. Cell Mol. Biol. 2001, 24, 317–325.
  46. Cao, W.; Baniecki, M.L.; McGrath, W.J.; Bao, C.; Deming, C.B.; Rade, J.J.; Lowenstein, C.J.; Mangel, W.F. Nitric oxide inhibits the adenovirus proteinase in vitro and viral infectivity in vivo. FASEB J. 2003, 17, 2345–2346.
  47. Klingström, J.; Åkerström, S.; Hardestam, J.; Stoltz, M.; Simon, M.; Falk, K.I.; Mirazimi, A.; Rottenberg, M.; Lundkvist, A. Nitric oxide and peroxynitrite have different antiviral effects against hantavirus replication and free mature virions. Eur. J. Immunol. 2006, 36, 2649–2657.
  48. Regev-Shoshani, G.; Vimalanathan, S.; McMullin, B.; Road, J.; Av-Gay, Y.; Miller, C. Gaseous nitric oxide reduces influenza infectivity in vitro. Nitric Oxide 2013, 31, 48–53.
  49. Jung, K.; Gurnani, A.; Renukaradhya, G.J.; Saif, L.J. Nitric oxide is elicited and inhibits viral replication in pigs infected with porcine respiratory coronavirus but not porcine reproductive and respiratory syndrome virus. Vet. Immunol. Immunopathol. 2010, 136, 335–339.
  50. Åkerström, S.; Gunalan, V.; Keng, C.T.; Tan, Y.-J.; Mirazimi, A. Dual effect of nitric oxide on SARS-CoV replication: Viral RNA production and palmitoylation of the S protein are affected. Virology 2009, 395, 1–9.
  51. Akaberi, D.; Krambrich, J.; Ling, J.; Luni, C.; Hedenstierna, G.; Järhult, J.D.; Lennerstrand, J.; Lundkvist, Å. Mitigation of the replication of SARS-CoV-2 by nitric oxide in vitro. Redox Biol. 2020, 37, 101734.
  52. Keyaerts, E.; Vijgen, L.; Chen, L.; Maes, P.; Hedenstierna, G.; Van Ranst, M. Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compound. Int. J. Infect. Dis. 2004, 8, 223–226.
  53. Åkerström, S.; Mousavi-Jazi, M.; Klingström, J.; Leijon, M.; Lundkvist, A.; Mirazimi, A. Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. J. Virol. 2005, 79, 1966–1969.
  54. Moilanen, E.; Vapaatalo, H. Nitric oxide in inflammation and immune response. Ann. Med. 1995, 27, 359–367.
  55. Koetzler, R.; Zaheer, R.S.; Wiehler, S.; Holden, N.S.; Giembycz, M.A.; Proud, D. Nitric oxide inhibits human rhinovirus-induced transcriptional activation of CXCL10 in airway epithelial cells. J. Allergy Clin. Immunol. 2009, 123, 201–208.e9.
  56. Guzik, T.J.; Korbut, R.; Adamek-Guzik, T. Nitric oxide and superoxide in inflammation and immune regulation. J. Physiol. Pharmacol. 2003, 54, 469–487.
  57. Kircheis, R.; Haasbach, E.; Lueftenegger, D.; Heyken, W.T.; Ocker, M.; Planz, O. NF-κB Pathway as a Potential Target for Treatment of Critical Stage COVID-19 Patients. Front. Immunol. 2020, 11, 598444.
  58. Hess, D.T.; Matsumoto, A.; Kim, S.-O.; Marshall, H.E.; Stamler, J.S. Protein S-nitrosylation: Purview and parameters. Nat. Rev. Mol. Cell Biol. 2005, 6, 150–166.
  59. Reynaert, N.L.; Ckless, K.; Korn, S.H.; Vos, N.; Guala, A.S.; Wouters, E.F.; van der Vliet, A.; Janssen-Heininger, Y.M. Nitric oxide represses inhibitory κB kinase through S-nitrosylation. Proc. Natl. Acad. Sci. USA 2004, 101, 8945–8950.
  60. Tejero, J.; Shiva, S.; Gladwin, M.T. Sources of Vascular Nitric Oxide and Reactive Oxygen Species and Their Regulation. Physiol. Rev. 2019, 99, 311–379.
  61. Tang, N.; Li, D.; Wang, X.; Sun, Z. Abnormal Coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost. 2020, 18, 844–847.
  62. Green, S.J. Covid-19 accelerates endothelial dysfunction and nitric oxide deficiency. Microbes Infect. 2020, 22, 149–150.
  63. Akter, F.; Coghlan, G.; de Mel, A. Nitric oxide in paediatric respiratory disorders: Novel interventions to address associated vascular phenomena? Ther. Adv. Cardiovasc. Dis. 2016, 10, 256–270.
  64. Friebe, A.; Sandner, P.; Schmidtko, A. cGMP: A unique 2nd messenger molecule—Recent developments in cGMP research and development. Naunyn-Schmiedeberg’s Arch. Pharmacol. 2020, 393, 287–302.
  65. Kamenshchikov, N.O.; Berra, L.; Carroll, R.W. Therapeutic Effects of Inhaled Nitric Oxide Therapy in COVID-19 Patients. Biomedicines 2022, 10, 369.
  66. Alqahtani, J.S.; Aldhahir, A.M.; Al Ghamdi, S.S.; AlBahrani, S.; AlDraiwiesh, I.A.; Alqarni, A.A.; Latief, K.; Raya, R.P.; Oyelade, T. Inhaled Nitric Oxide for Clinical Management of COVID-19: A Systematic Review and Meta-Analysis. Int. J. Environ. Res. Public Health 2022, 19, 12803.
  67. Chen, L.; Liu, P.; Gao, H.; Sun, B.; Chao, D.; Wang, F.; Zhu, Y.; Hedenstierna, G.; Wang, C.G. Inhalation of nitric oxide in the treatment of severe acute respiratory syndrome: A rescue trial in Beijing. Clin. Infect. Dis. 2004, 39, 1531–1535.
  68. Parikh, R.; Wilson, C.; Weinberg, J.; Gavin, D.; Murphy, J.; Reardon, C.C. Inhaled nitric oxide treatment in spontaneously breathing COVID-19 patients. Ther. Adv. Respir. Dis. 2020, 14, 1753466620933510.
  69. Safaee Fakhr, B.; Di Fenza, R.; Gianni, S.; Wiegand, S.B.; Miyazaki, Y.; Araujo Morais, C.C.; Gibson, L.E.; Chang, M.G.; Mueller, A.L.; Rodriguez-Lopez, J.M.; et al. Inhaled high dose nitric oxide is a safe and effective respiratory treatment in spontaneous breathing hospitalized patients with COVID-19 pneumonia. Nitric Oxide 2021, 116, 7–13.
  70. Safaee Fakhr, B.; Wiegand, S.B.; Pinciroli, R.; Gianni, S.; Morais, C.C.A.; Ikeda, T.; Miyazaki, Y.; Marutani, E.; Di Fenza, R.; Larson, G.M.; et al. High Concentrations of Nitric Oxide Inhalation Therapy in Pregnant Patients with Severe Coronavirus Disease 2019 (COVID-19). Obstet. Gynecol. 2020, 136, 1109–1113.
  71. Zamanian, R.T.; Pollack, C.V., Jr.; Gentile, M.A.; Rashid, M.; Fox, J.C.; Mahaffey, K.W.; de Jesus Perez, V. Outpatient Inhaled Nitric Oxide in a Patient with Vasoreactive Idiopathic Pulmonary Arterial Hypertension and COVID-19 Infection. Am. J. Respir. Crit. Care Med. 2020, 202, 130–132.
  72. Alvarez, R.A.; Berra, L.; Gladwin, M.T. Home Nitric Oxide Therapy for COVID-19. Am. J. Respir. Crit. Care Med. 2020, 202, 16–20.
  73. Caplan, M.; Goutay, J.; Bignon, A.; Jaillette, E.; Favory, R.; Mathieu, D.; Parmentier-Decrucq, E.; Poissy, J.; Duburcq, T.; Lille Intensive Care COVID-19 Group. Almitrine Infusion in Severe Acute Respiratory Syndrome Coronavirus 2-Induced Acute Respiratory Distress Syndrome: A Single-Center Observational Study. Crit. Care Med. 2020, 49, e191–e198.
  74. Bagate, F.; Tuffet, S.; Masi, P.; Perier, F.; Razazi, K.; de Prost, N.; Carteaux, G.; Payen, D.; Mekontso Dessap, A. Rescue therapy with inhaled nitric oxide and almitrine in COVID-19 patients with severe acute respiratory distress syndrome. Ann. Intensiv. Care 2020, 10, 151.
  75. Laghlam, D.; Rahoual, G.; Malvy, J.; Estagnasié, P.; Brusset, A.; Squara, P. Use of Almitrine and Inhaled Nitric Oxide in ARDS Due to COVID-19. Front. Med. 2021, 8, 655763.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
ScholarVision Creations
Feedback